Therefore, we conducted the TIDE algorithm and subclass mapping to compare the expression profile of the two subgroups and another published dataset containing 47 patients with melanoma that responded to immune checkpoint inhibitors (CTLA-4 and PD-1). Here, CTLA4 is linked to melanoma.